Society of Diabetic Nephropathy Prevention Journal of Nephropathology 2251-8363 9 2 2020 04 01 A case of Fanconi syndrome as a complication of treatment with a checkpoint inhibitor in a patient with hepatocellular carcinoma e19 e19 10.34172/jnp.2020.19 EN Mohammad Tinawi Bahar Bastani https://orcid.org/0000-0002-2138-4248 Journal Article 10.34172/jnp.2020.19 2019 07 04 2019 07 27 Introduction: Immune checkpoint inhibitors (CPIs) represent novel new cancer immunotherapy agents. The use of nivolumab has been linked with immune mediated acute interstitial nephritis (AIN). Case Presentation: We present the case of a patients with recurrent hepatocellular carcinoma who developed severe Fanconi syndrome, as evidenced by hyperchloremic metabolic acidosis, hypokalemia, hypophosphatemia, glucosuria, aminoaciduria, 8 months after initiating treatment with nivolumab, without any evidence of acute renal insufficiency. Conclusion: Clinicians need to be aware of the renal side effects of new novel cancer immunotherapy agents, such as, immune CPIs